Prevalence of hypothyroidism in adults: An epidemiological study in eight cities of India

Ambika Gopalakrishnan Unnikrishnan, Sanjay Kalra¹, Rakesh Kumar Sahay², Ganapathi Bantwal³, Mathew John⁴, Neeraj Tewari⁵

Department of Endocrinology, Amrita Institute of Medical Sciences, Cochin, Kerala, ¹Bharti Research Institute of Diabetes and Endocrinology (BRIDE), Bharti Hospital, Wazir Chand Colony, Kunjipura Road, Karnal, Haryana, ²Osmania Medical College and Osmania General Hospital, Hyderabad, Andhra Pradesh; ³St. John’s Medical College and Hospital, Bangalore, Karnataka, ⁴Providence Endocrine and Diabetes Specialty Centre, Murinjapalam, Trivandrum, Kerala, India, ⁵Medical Affairs (Endocrinology and Metabolism) Abbott India Limited, Goregaon East, Mumbai, Maharashtra, India

ABSTRACT

Background: Hypothyroidism is believed to be a common health issue in India, as it is worldwide. However, there is a paucity of data on the prevalence of hypothyroidism in adult population of India. Materials and Methods: A cross-sectional, multi-centre, epidemiological study was conducted in eight major cities (Bangalore, Chennai, Delhi, Goa, Mumbai, Hyderabad, Ahmedabad and Kolkata) of India to study the prevalence of hypothyroidism among adult population. Thyroid abnormalities were diagnosed on the basis of laboratory results (serum FT3, FT4 and Thyroid Stimulating Hormone [TSH]). Patients with history of hypothyroidism and receiving levothyroxine therapy or those with serum free T4 <0.89 ng/dl and TSH >5.50 μIU/ml, were categorized as hypothyroid. The prevalence of self reported and undetected hypothyroidism, and anti-thyroid peroxidase (anti-TPO) antibody positivity was assessed. Results: A total of 5376 adult male or non-pregnant female participants ≥18 years of age were enrolled, of which 5360 (mean age: 46 ± 14.68 years; 53.70% females) were evaluated. The overall prevalence of hypothyroidism was 10.95% (n = 587, 95% CI, 10.11-11.78) of which 7.48% (n = 401) patients self reported the condition, whereas 3.47% (n = 186) were previously undetected. Inland cities showed a higher prevalence of hypothyroidism as compared to coastal cities. A significantly higher (P < 0.05) proportion of females vs. males (15.86% vs 5.02%) and older vs. younger (13.11% vs 7.53%), adults were diagnosed with hypothyroidism. Additionally, 8.02% (n = 430) patients were diagnosed to have subclinical hypothyroidism (normal serum free T4 and TSH >5.50 μIU/ml). Anti – TPO antibodies suggesting autoimmunity were detected in 21.85% (n = 1171) patients. Conclusion: The prevalence of hypothyroidism was high, affecting approximately one in 10 adults in the study population. Female gender and older age were found to have significant association with hypothyroidism. Subclinical hypothyroidism and anti-TPO antibody positivity were the other common observations. Key words: Anti-TPO positive, epidemiology, free T3, free T4, hypothyroidism, India, prevalence, subclinical hypothyroidism, undetected hypothyroidism

INTRODUCTION

Hypothyroidism is characterized by a broad clinical spectrum ranging from an overt state of myxedema, end-organ effects and multisystem failure to an asymptomatic or subclinical condition with normal levels of thyroxine and triiodothyronine and mildly elevated levels of serum thyrotropin.[1,4] The prevalence of hypothyroidism in the developed world is about 4-5%.5,6 The prevalence of subclinical hypothyroidism in the developed world is about 4-15%.5,7

In a developing and densely populated country like India, communicable diseases are priority health concerns due to their large contribution to the national disease burden.8 In India, hypothyroidism was usually categorized under
the cluster of iodine deficient disorders (IDDs), which were represented in terms of total goiter rates and urinary iodine concentrations, typically assessed in school-aged children. There since India adopted the universal salt iodization program in 1983, there has been a decline in goiter prevalence in several parts of the country, which were previously endemic. In 2004, a WHO assessment of global iodine status classified India as having ‘optimal’ iodine nutrition, with a majority of households (83.2% urban and 66.1% rural) now consuming adequate iodized salt. India is supposedly undergoing a transition from iodine deficiency to sufficiency state. A recent review of studies conducted in the post-iodization era. The aim of the present study was to estimate the prevalence of hypothyroidism among the adult population in India.

**Materials and Methods**

**Study design and enrollment criteria**

This was a cross-sectional, multi-centered epidemiology study conducted at eight sites in India namely Bangalore, Chennai, Delhi, Goa, Ahmedabad, Hyderabad, Kolkata and Mumbai. These cities were selected to ensure participation of a diverse study population with respect to geographic origin, occupation, socioeconomic status and food habits. Primary outcome measure of the study was the prevalence of hypothyroidism assessed by measurement of thyroid hormones. Secondary outcome measures were the prevalence of: i) self-reported and undetected hypothyroidism, ii) sub-clinical hypothyroidism (SCH) and iii) anti-thyroid peroxidase (TPO) antibody positivity in the study population. All male or female natives (residing in that area for at least 5 years) aged ≥18 years, were invited to participate in a general health checkup camp, and those willing to sign a written informed consent and provide blood sample for laboratory investigations were included in the study. Participants were excluded if they were pregnant, or had any acute or chronic systemic illnesses as judged by investigator; or if they were receiving drugs (like lithium or steroids) that could interfere with thyroid function tests. The study was approved by a Central Ethics Committee (CEC) and carried out in accordance with the approved protocol, principles of Declaration of Helsinki and Good Clinical Practices. It was registered with the Clinical Trials Registry India (registration no: CTRI/2011/11/002180). All participants were required to provide written informed consent before study entry.

**Subjects**

Enrolment of 5277 participants was planned to form a target population that constituted 0.01% of the total population of the eight cities. Sample size for each city was calculated by performing stratification according to the 2001 national census data. Participants were selected through a single visit they made to any one of the 94 general health camps organized across the eight cities. For creating awareness of each general health camp, 5000-6000 invitation leaflets were distributed door to door covering approximately five kilometers area around the camp venue, banners were exhibited at appropriate areas and 8-10 general health camp posters were displayed in the vicinity of the camps. The general health camps were led by physicians certified in internal medicine.

**Study procedure**

Before enrolment, participants underwent medical history assessment, a general physical examination (including anthropometry and thyroid gland examination) and laboratory investigations. A central certified laboratory performed the hematological and biochemical investigations. Assays for thyroid hormone (FT3, FT4 and TSH) were performed by the chemiluminescence method using Advia Centaur automated immunoassay analyzer (Siemens Diagnostics Tarrytown, NY, USA). Anti-TPO antibodies were measured by the enzyme-linked immunosorbent assay (ELISA) using Immulite 2000 (Siemens Diagnostics Llanberis, Gwynedd, UK). Analytical sensitivity of the kit used to measure TSH, FT3, FT4 and anti-TPO antibodies was 0.010 μIU/mL, 0.1 ng/mL, 0.3 μg/dL and 5.0 IU/mL, respectively.

Based on previous thyroid history and current thyroid function test results, participants were classified using following definitions: 

- **Hypothyroid:** Serum-free thyroxine (FT4) <0.89 ng/dL and thyroid stimulation hormone (TSH) >5.50 μIU/mL,
- **Hyperthyroid:** Serum FT4 >1.76 ng/dL and TSH <0.35 μIU/mL,
- **Subclinical hypothyroid:** Normal serum FT4 and TSH >5.50 μIU/mL,
- **Subclinical hyperthyroid:** Normal serum FT4 and TSH <0.35 μIU/mL,
- **Self-reported hypothyroidism:** Subjects with history of hypothyroidism and taking levothyroxine therapy,
- **Undetected Hypothyroidism:** Subjects without history of hypothyroidism and detected to have hypothyroidism through thyroid function tests. **Anti-TPO antibody positive:** Presence of anti-TPO antibodies above 35 IU/mL.

**Materials and Methods**

**Study design and enrollment criteria**

This was a cross-sectional, multi-centered epidemiology study conducted at eight sites in India namely Bangalore, Chennai, Delhi, Goa, Ahmedabad, Hyderabad, Kolkata and Mumbai. These cities were selected to ensure participation of a diverse study population with respect to geographic origin, occupation, socioeconomic status and food habits. Primary outcome measure of the study was the prevalence of hypothyroidism assessed by measurement of thyroid hormones. Secondary outcome measures were the prevalence of: i) self-reported and undetected hypothyroidism, ii) sub-clinical hypothyroidism (SCH) and iii) anti-thyroid peroxidase (TPO) antibody positivity in the study population. All male or female natives (residing in that area for at least 5 years) aged ≥18 years, were invited to participate in a general health checkup camp, and those willing to sign a written informed consent and provide blood sample for laboratory investigations were included in the study. Participants were excluded if they were pregnant, or had any acute or chronic systemic illnesses as judged by investigator; or if they were receiving drugs (like lithium or steroids) that could interfere with thyroid function tests. The study was approved by a Central Ethics Committee (CEC) and carried out in accordance with the approved protocol, principles of Declaration of Helsinki and Good Clinical Practices. It was registered with the Clinical Trials Registry India (registration no: CTRI/2011/11/002180). All participants were required to provide written informed consent before study entry.

**Subjects**

Enrolment of 5277 participants was planned to form a target population that constituted 0.01% of the total population of the eight cities. Sample size for each city was calculated by performing stratification according to the 2001 national census data. Participants were selected through a single visit they made to any one of the 94 general health camps organized across the eight cities. For creating awareness of each general health camp, 5000-6000 invitation leaflets were distributed door to door covering approximately five kilometers area around the camp venue, banners were exhibited at appropriate areas and 8-10 general health camp posters were displayed in the vicinity of the camps. The general health camps were led by physicians certified in internal medicine.

**Study procedure**

Before enrolment, participants underwent medical history assessment, a general physical examination (including anthropometry and thyroid gland examination) and laboratory investigations. A central certified laboratory performed the hematological and biochemical investigations. Assays for thyroid hormone (FT3, FT4 and TSH) were performed by the chemiluminescence method using Advia Centaur automated immunoassay analyzer (Siemens Diagnostics Tarrytown, NY, USA). Anti-TPO antibodies were measured by the enzyme-linked immunosorbent assay (ELISA) using Immulite 2000 (Siemens Diagnostics Llanberis, Gwynedd, UK). Analytical sensitivity of the kit used to measure TSH, FT3, FT4 and anti-TPO antibodies was 0.010 μIU/mL, 0.1 ng/mL, 0.3 μg/dL and 5.0 IU/mL, respectively.

Based on previous thyroid history and current thyroid function test results, participants were classified using following definitions: 

- **Hypothyroid:** Serum-free thyroxine (FT4) <0.89 ng/dL and thyroid stimulation hormone (TSH) >5.50 μIU/mL,
- **Hyperthyroid:** Serum FT4 >1.76 ng/dL and TSH <0.35 μIU/mL,
- **Subclinical hypothyroid:** Normal serum FT4 and TSH >5.50 μIU/mL,
- **Subclinical hyperthyroid:** Normal serum FT4 and TSH <0.35 μIU/mL,
- **Self-reported hypothyroidism:** Subjects with history of hypothyroidism and taking levothyroxine therapy,
- **Undetected Hypothyroidism:** Subjects without history of hypothyroidism and detected to have hypothyroidism through thyroid function tests. **Anti-TPO antibody positive:** Presence of anti-TPO antibodies above 35 IU/mL.
**Statistical analysis**

Statistical analysis was performed using SAS® for Windows (Version 9.2, SAS Institute). The analysis was performed on the set of all eligible subjects enrolled in the study according to the study protocol. The prevalence of hypothyroidism and other thyroid disorders was summarized as counts and percentages. A Chi-square test was used to assess the trends in the prevalence of hypothyroidism, among different age groups and gender categories. Multiple Logistic Regression was used to describe factors associated with hypothyroidism, using ‘whether the subject has hypothyroidism or not’ as the dependent variable and ‘Age’ and ‘Gender’ as the independent variables. Similar analyses were performed for SCH and anti-TPO antibody positivity.

**RESULTS**

Five thousand three hundred and seventy six (5376) participants were enrolled across eight urban cities in India, from March 2011 to July 2011. Sixteen participants were withdrawn due to ineligibility (n = 11) or lack of laboratory data (n = 5). Out of the 5360 analyzable subjects, 2932 (54.70%) were females [Table 1]. The mean age of the study subjects was 45.85 with a range of 18 to 100 years. Hypertension (n = 1095; 20.4%) and diabetes mellitus (n = 866; 16.2%) were the most common concomitant diseases observed in the study population. Five hundred and ninety eight (11.15%) participants gave history of thyroid dysfunction including thyroid surgery. Thyroid medications were in current or previous use in approximately 8% (n = 408) of the population. A majority (88.27%; n = 4731) of the study population (n = 5360) was reportedly consuming iodized salt.

**Hypothyroidism**

The prevalence of hypothyroidism in the overall study population was 10.95% (n = 587, 95% CI, 10.11-11.78) of which 3.47% (n = 186) were previously undetected and 7.48% (n = 401) were self-reported cases. Positive history of hypothyroidism was given by 427 subjects, however only 401 of them were on thyroxine therapy. Out of these 401 self reported cases accurate dosing details of thyroxine therapy were available with 379 patients. Among these 379 patients 587 (71.77%) had a TSH <5.5 μIU/mL on a mean dose of 1.19 mcg/kg, while the remaining (n = 107, 28.23%) had a TSH >5.5 μIU/mL on a mean dose of 1.10 mcg/kg.

Among all cities, Kolkata recorded the highest prevalence of hypothyroidism (21.67%), while others showed comparable rates ranging from 8.88% (Hyderabad) to 11.07% (Delhi) [Table 2]. Cities located in the in-land regions of India (Delhi, Ahmedabad, Kolkata, Bangalore

---

**Table 1: Demographic characteristics and thyroid related history of the study population**

| Total subjects | 5360 |
|----------------|------|
| Gender, n (%)  |      |
| Female         | 2932 (54.70) |
| Male           | 2428 (45.30) |
| Age (years)    |      |
| Mean±SD        | 45.85±14.68 |
| Min-Max (years)| 18-100 |
| Age-group, n (%)|     |
| 18-35 years    | 1447 (27.00) |
| 36-45 years    | 1244 (23.21) |
| 46-54 years    | 1068 (19.93) |
| 55 and above   | 1601 (29.87) |
| Common concurrent conditions, n (%) |    |
| Diabetes mellitus | 866 (16.16) |
| Hypertension    | 1095 (20.43) |
| History of thyroid disease, n (%) |   |
| Hypothyroid     | 427 (7.97) |
| Hyperthyroid    | 17 (0.34) |
| Goitre          | 116 (2.25)* |
| Thyroid malignancy | 6 (0.11) |
| Subacute viral thyroiditis | 2 (0.04) |
| History of thyroid surgery, n (%) | 13 (0.24) |
| Current or past thyroid medications, n (%) | |
| Levethoxine     | 379 (7.07) |
| Thyroid supplements | 15 (0.27) |
| Carbimazole     | 13 (0.24) |
| Methimazole     | 1 (0.02) |

*For history of goiter, 4 observations were missing

---

**Table 2: Prevalence of thyroid disorders in eight urban cities of India**

| City         | n   | Hypothyroidism n (%) | Self reported, hypothyroidism n (%) | Undetected hypothyroidism n (%) | Subclinical hypothyroidism n (%) | Hyperthyroidism n (%) | Subclinical hyperthyroidism n (%) | Anti-TPO positivity n (%) |
|--------------|-----|----------------------|-------------------------------------|---------------------------------|---------------------------------|------------------------|----------------------------------|---------------------------|
| Ahmedabad    | 377 | 40 (10.61)           | 31 (8.22)                           | 9 (2.39)                        | 27 (7.16)                      | 3 (0.8)                | 2 (0.53)                        | 50 (13.26)                 |
| Bangalore    | 867 | 80 (9.23)            | 47 (5.42)                           | 33 (3.81)                       | 63 (7.27)                      | 7 (0.81)               | 9 (1.04)                        | 151 (17.42)               |
| Chennai      | 430 | 42 (9.77)            | 33 (7.67)                           | 9 (2.09)                        | 23 (5.35)                      | 2 (0.47)               | 7 (1.63)                        | 111 (25.81)               |
| Delhi        | 1436| 159 (11.07)          | 102 (7.10)                          | 57 (3.97)                       | 138 (9.61)                     | 5 (0.35)               | 15 (1.04)                       | 316 (22.01)               |
| Goa          | 142 | 10 (7.04)            | 4 (2.82)                            | 6 (4.23)                        | 6 (4.23)                       | 1 (0.7)                | 5 (3.52)                        | 26 (18.31)                |
| Hyderabad    | 383 | 34 (8.88)            | 15 (3.92)                           | 19 (4.96)                       | 28 (7.31)                      | 2 (0.52)               | 5 (1.31)                        | 91 (23.76)                |
| Kolkata      | 466 | 101 (21.67)          | 84 (18.03)                          | 17 (3.65)                       | 55 (11.8)                      | 5 (1.07)               | 2 (0.43)                        | 106 (22.75)               |
| Mumbai       | 1259| 121 (9.61)           | 85 (6.75)                           | 36 (2.86)                       | 99 (7.85)                      | 11 (0.87)              | 23 (1.83)                       | 320 (25.42)               |
| Total        | 5360| 587 (10.95)          | 401 (7.48)                          | 186 (3.47)                      | 430 (8.02)                     | 36 (0.67)              | 68 (1.27)                       | 1,171 (21.85)             |

TPO: Thyroid peroxidase
and Hyderabad) reported a significantly higher prevalence of hypothyroidism (11.73%) than those (Mumbai, Chennai and Goa) in the coastal areas (9.45%), \( P = 0.01 \). Logistic Regression Analysis demonstrated a statistically significant \( (P < 0.05) \) interaction of patient age and gender with the prevalence of hypothyroidism. As compared to young adults (aged 18-35 years), older adults had greater chances of being diagnosed of hypothyroidism (36-45 years: \( OR = 1.49, 95\% CI: 1.14-1.94, P = 0.0036 \); 46-54 years: \( OR = 1.53, 95\% CI: 1.16-2.01, P = 0.0024 \); 55 years and above: \( OR = 1.56, 95\% CI: 1.21-2.02, P = 0.0006 \)). The prevalence of hypothyroidism was the highest in the age-group of 46 to 54 years (13.11%) and the lowest in that of 18 to 35 years (7.53%).

A larger proportion of females than males (15.86% vs. 5.02%; \( P < 0.0001 \)) were found to be affected by hypothyroidism. Females were also more likely to be detected with hypothyroidism than males (\( OR = 3.36, 95\% CI: 2.720-4.140, P < 0.0001 \)).

**Subclinical hypothyroidism**

Subclinical hypothyroidism (SCH) was observed in 430 (8.02%, 95% CI: 7.29-8.74) participants. Frequency of SCH was highest (8.93%) in the age group of above 55 years and lowest in the age group of 18-35 years (6.91%), though no statistically significant association was found with age \( (P = 0.1534) \). A significantly higher number of females (8.73%) than males (7.17%, \( P = 0.0358 \)) were detected to have SCH.

**Anti-TPO antibodies**

A total of 1171 (21.85%, 95% CI, 20.74-22.95) subjects tested positive for anti-TPO antibody. The anti-TPO positivity was consistently high, with five cities recording a prevalence of more than 20%. Lowest prevalence of anti-TPO antibodies was seen in Ahmedabad (13.26%) while highest prevalence was seen in Chennai (25.81%).

There was no significant association \( (P = 0.1796) \) between age and the presence of anti-TPO antibodies. Females showed a greater prevalence (26.04%) than males (16.81%), \( P < 0.05 \). Females in the age group of 46-54 had the highest prevalence (27.86%) of anti-TPO antibodies.

**Hyperthyroidism**

A total of 36 (0.67%, 95% CI, 0.45-0.89) participants including 21 females (0.72%) were diagnosed with hyperthyroidism. There was no association \( (P > 0.05) \) between hyperthyroidism and age or gender. Subclinical hyperthyroidism was seen in 68 (1.27%, 95% CI, 0.96-1.56) patients.

**DISCUSSION**

In the present study, we assessed the nationwide prevalence of thyroid disorders, particularly hypothyroidism, in adults residing in various urban cities that represent diverse geographical regions of India. Hypothyroidism was found to be a common form of thyroid dysfunction affecting 10.9% of the study population. The prevalence of undetected hypothyroidism was 3.47% i.e., almost one-third of the hypothyroid patients (186 out of 587) were diagnosed for the first time during the course of study-related screening. This suggests that a significant proportion of patient population may go undetected and untreated even as it continues to impair the daily quality of life, work performance and economic productivity of an individual.

On the other hand, among the subjects who self-reported themselves to be hypothyroid, a significant proportion (28%) still had a high TSH value. This calls for a review of current practices in the management of thyroid disorders, including active screening of endocrine function among patients at greater risks and an emphasis on regular monitoring of the thyroid status and dose adjustments to provide effective therapy in those with established diagnosis.

In general, India is now considered to be in the post-iodization phase.[17] Our results suggest that, nationwide, the prevalence of hypothyroidism in adults is very high in this era. Unfortunately, no prevalence data exist on the occurrence of hypothyroidism among adults in the pre-iodization phase. The slight, but statistically significant increased prevalence of hypothyroidism among the inland vs. coastal cities in our study leads us to speculate whether iodine deficiency may continue to play a role in hypothyroidism in India.

The emergence of Kolkata as the worst affected city was unanticipated, particularly as the city was established to be iodine replete over a decade back.[29] However, in a comparable geographical area of Gangetic basin in West Bengal, the prevalence of hypothyroidism in 3814 subjects from all age groups was even higher (29%).[20] The high prevalence figures in Kolkata have ascertained that thyroid disorders in India are not confined to the conventional iodine-deficient sub-Himalayan zone but also extended to the plain fertile lands. A possible etiological role of cyanogenic foods acting as goitrogens to interfere with iodine nutrition has been previously suggested for, but not limited to this area.[27,28] Increasing exposure to thyroid disruptors including industrial and agricultural contaminants has been identified as a growing health concern throughout India.[29]
There was a predominance of thyroid dysfunction in women in our study, and is consistent with worldwide reports, especially those in midlife (46-54 years). Given the association between thyroid disorders and cardiovascular risk factors such as hypertension and dyslipidemia, the prevalence figures noted for women in this study draw attention to the growing health needs of this important segment of the Indian population.

Another significant observation was that approximately one fifth of the study population had anti-TPO positivity, which is an established marker of autoimmune thyroid disease. There seems to be a steady rise in the prevalence of anti-TPO positive in India. In a study conducted from 2007 to 2010 in Delhi, the percentage of adults testing TPO antibody positive was 13.3% the figure was 22.01% in the current study. A similar increase was apparently observed in the southern part of India. Earlier, Kerala saw a 16.7% prevalence in 2007 to 2010 in Delhi, the percentage of adults testing TPO antibody positive was 13.3% the figure was 22.01% in the current study. A similar increase was apparently observed in the southern part of India. Earlier, Kerala saw a 16.7% prevalence in adults, and the rate in a neighboring state (represented by Chennai) reported in the current study is 25.81%. Reasons for the increase in anti-TPO positivity remain unclear; the underlying pathogenesis may involve a complex interplay of genetic, environmental and endogenous factors.

Our study has important limitations: Firstly, it was done in urban India, and the prevalence of hypothyroidism in rural India remains unknown. Secondly, from the consumption of iodized salt, the study presumed that the target population was iodine sufficient, without testing for reliable markers such as iodine content in salt samples or urinary iodine excretion. Thus, with regard to the cause of hypothyroidism, there may be etiological factors other than the iodization status.

To summarize the present study is to first provide nationwide data on the prevalence of hypothyroidism in the adult population. The study shows a high prevalence of hypothyroidism and positivity to anti-TPO antibodies. This poses a public health concern and an important challenge to the policy makers and health professionals.

**CONCLUSIONS**

Hypothyroidism is a commonly prevailing disorder in adult Indian population. Older overweight females seem to be more prone. Autoimmune mechanisms appear to play an etiological role in a significant proportion of patients. Iodine intake ceases to be the sole etiological contender for thyroid disorders in urban areas. Identification of multiple risk factors and plausible underlying mechanisms is warranted.

**ACKNOWLEDGMENT**

This work was funded by Abbott India Limited. The authors acknowledge the valuable contribution of the following participating investigators (centers in alphabetical order): Dr. Sanjeev Phatak, MD (Ahmedabad), Dr. Arun Vadavi, MD (Bangalore), Dr. E. Prabhu, MD (Chennai), Dr. Raj Kumar Lalwani, MD (Delhi); Dr. Rufino Monteiro, MD (Goa), Dr. Loy Camoens, MD (Hyderabad); Dr. Mary D’Cruz, MD (Kolkata) and Dr. Mahesh Padsalge, MD (Mumbai).

**REFERENCES**

1. Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med 2001;345:260-5.
2. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004;363:793-803.
3. Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 2004;24:1-13.
4. Krassas GE, Poppe K, Glinos D. Thyroid function and human reproductive health. Endocr Rev 2010;31:702-55.
5. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T4 (4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-99.
6. Hoogendoorn EH, Hermus AR, de Vogt F, Ross HA, Verbeek AL, Kiemency LA, et al. Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: Influences of age and sex. Clin Chem 2006;52:104-11.
7. Bemben DA, Hamm RM, Morgan L, Winn P, Davis A, Barton E. Thyroid disease in the elderly. Part 2. Predictability of subclinical hypothyroidism. J Fam Pract 1994;38:583-8.
8. National Commission on Macroeconomics and Health Ministry of Health and Family Welfare, Government of India, New Delhi: Background Papers-Burden of Disease in India; 2005.
9. Sood A, Pandav CS, Anand K, Sankar R, Karmarkar MG. Relevance and importance of universal salt iodization in India. Natt Med J India 1997;10:290-3.
10. Kapil U, Saxena N, Ramachandran S, Balamurugan A, Nayyar D, Prakash S. Assessment of iodine deficiency disorders using the 30 cluster approach in the National Capital Territory of Delhi. Indian Pediart 996;33:1013-7.
11. Dodd NS, Godhia ML. Prevalence of iodine deficiency disorders in adolescents. Indian J Pediart 1992;59:585-91.
12. Tiwari BK, Ray I, Malhotra RL, Policy Guidelines on National Iodine Deficiency Disorders Control Programme-Nutrition and IDD Cell. Directorate of Health Services, Ministry of Health and Family Welfare. New Delhi: Government of India; 2006. p. 1-22.
13. Toteja GS, Singh P, Dhillon BS, Saxena BN. Iodine deficiency disorders in 15 districts of India. Indian J Pediart 2004;71:25-8.
14. Marwaha RK, Tandon N, Gupta N, Karak AK, Verma K, Kochupillai N. Residual goitre in the postiodization phase: Iodine status, thiocyanate exposure and autoimmunity. Clin Endocrinol (Oxf) 2003;59:672-81.
15. Kapil U, Sharma TD, Singh P. Iodine status and goiter prevalence after 40 years of salt iodisation in the Kangra District, India. Indian J Pediart 2007;74:135-7.
16. Iodine status worldwide, WHO global database on iodine deficiency, Department of nutrition for health and development. Geneva: WHO; 2004.
17. Andersson M, Takkouche B, Egli I, Allen HE, Benoist B. Current
global iodine status and progress over the last decade towards the elimination of iodine deficiency. Bull World Health Organ 2002;80:518-25.

18. Sunderesan S. Progress achieved in universal salt iodization programme in India. In: Prakash R, Sunderesan S, Kapil U, editors. Proceedings of symposium on elimination of IDD through universal access to iodized salt. New Delhi: Shivshar Computer and Publications; 1998. p. 28-42.

19. Yadav K, Pandav CS, Karmarkar MG. Adequately iodized salt covered seventy-one percent of India in 2009. IDD newsletter 2011;39:2-5. Available from: http://www.seen.es/pdf/IDD%20NL%20email%20May%202011.pdf. [Last accessed on 2012 Jun 11].

20. Unnikrishnan AG, Menon UV. Thyroid disorders in India: An epidemiological perspective. Indian J Endocrinol Metab 2011;15:S78-81.

21. Rao RS, Kamath R, Das A, Nair NS, Keshavamurthy. Prevalence of goitre among school children in coastal Karnataka. Indian J Pediatr 2002;69:477-9.

22. Sankar R, Moorthy D, Pandav CS, Tiwari JS, Karmarkar MG. Tracking progress towards sustainable elimination of iodine deficiency disorders in Bihar. Indian J Pediatr 2006;73:799-802.

23. Kapil U, Sethi V, Goindli G, Pathak P, Singh P. Elimination of iodine deficiency disorders in Delhi. Indian J Pediatr 2004;71:211-2.

24. Marwaha RK, Tandon N, Garg MK, Desai A, Kanwar R, Sastry A, et al. Thyroid status two decades after salt iodization: Country-wide data in school children from India. Clin Endocrinol (Oxf) 2012;76:905-10.

25. Sinha RK, Bhattacharya A, Roy BK, Saha SK, Nandy P, Doloi M, et al. Body iodine status in school children and availability of iodised salt in Calcutta. Indian J Public Health 1999;43:42-8.

26. Chandra AK, Tripathy S, Mukhopadhyay S, Lahari D. Studies on endemic goitre and associated iodine deficiency disorders (IDD) in a rural area of the Gangetic West Bengal. Indian J Nutr Diet 2003;40:53-8.

27. Chandra AK, Tripathy S, Lahari D, Mukhopadhyay S. Iodine nutritional status of school children in a rural area of Howrah district in the Gangetic West Bengal. Indian J Physiol Pharmacol 2004;48:219-24.

28. Chandra AK, Mukhopadhyay S, Lahari D, Tripathy S. Goitrogenic content of Indian cyanogenic plant foods and their in vitro anti-thyroidal activity. Indian J Med Res 2004;119:180-5.

29. Kalra S, Unnikrishnan AG, Sahay RK. Thyroidology and public health: The challenges ahead. Indian J Endocrinol Metab 2011;15:S73-5.

30. Luboshitzky R, Herer P. Cardiovascular risk factors in middle-aged women with subclinical hypothyroidism. Neuro Endocrinol Lett 2004;25:262-6.

31. Demers LM, Spencer CA. Laboratory medicine practice guidelines: Laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf) 2003;58:138-40.

32. Marwaha RK, Tandon N, Ganie MA, Kanwar R, Garg MK, Singh S. Status of thyroid function in Indian adults: Two decades after universal salt iodization. J Assoc Physicians India 2012;60:32-6.

33. Usha Menon V, Sundaram KR, Unnikrishnan AG, Jayakumar RV, Nair V, Kumar H. High prevalence of undetected thyroid disorders in an iodine sufficient adult south Indian population. J Indian Med Assoc 2009;107:72-7.

34. Gopalakrishnan S, Singh SP, Prasad WR, Jain SK, Ambardar VK, Sankar R. Prevalence of goitre and autoimmune thyroiditis in schoolchildren in Delhi, India, after two decades of salt iodisation. J Pediatr Endocrinol Metab 2006;19:889-93.

35. Papapanastasiou L, Vatalas IA, Koutras DA, Mastorakos G. Thyroid autoimmunity in the current iodine environment. Thyroid 2007;17:729-39.

36. Brent GA. Environmental exposures and autoimmune thyroid disease. Thyroid 2010;20:755-61.

37. WHO/UNICEF/ICCIDD. Indicators for assessing Iodine Deficiency Disorders and their control through salt iodization. Geneva, WHO/NUT/94.6. 1994.

Cite this article as: Unnikrishnan AG, Kalra S, Sahay RK, Bantwal G, John M, Tewari N. Prevalence of hypothyroidism in adults: An epidemiological study in eight cities of India. Indian J Endocrinol Metab 2013;17:547-52.

Source of Support: Nil, Conflict of Interest: None declared.

Staying in touch with the journal

1) Table of Contents (TOC) email alert
Receive an email alert containing the TOC when a new complete issue of the journal is made available online. To register for TOC alerts go to www.ijem.in/signup.asp.

2) RSS feeds
Really Simple Syndication (RSS) helps you to get alerts on new publication right on your desktop without going to the journal’s website. You need a software (e.g. RSSReader, Feed Demon, FeedReader, My Yahoo!, NewsGator and NewzCrawler) to get advantage of this tool. RSS feeds can also be read through Firefox or Microsoft Outlook 2007. Once any of these small (and mostly free) software is installed, add www.ijem.in/rssfeed.asp as one of the feeds.